CONFERENCE COVERAGE SERIES

Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention

Natcher Auditorium, National Institutes of Health, Bethesda, Maryland, U.S.A.

14 – 15 May 2012

Tools

Back to the Top

The first asymptomatic treatment trial of an investigational Alzheimer's immunotherapy got the go-ahead when a three-way collaboration among the biotech company Genentech, the federal government, and private philanthropy was forged to fund it and to provide both drug and expertise.

The five-year trial will test the antibody crenezumab in Colombian carriers of the Paisa mutation in presenilin-1, and in some U.S. carriers of other presenilin and APP mutations. At the Alzheimer's Disease Research Summit 2012 in Washington, D.C., NIH Director Francis Collins announced that the trial, as well as a second trial of intranasal insulin in MCI, were part of the National Plan to Address Alzheimer’s Disease, which HHS Secretary Kathleen Sebelius released on 15 May 2012.